Search

everythinglearnresearchcommunity

for

Search:↓

A female user is experiencing severe hair loss, especially at the crown and front, with broken and dull hair despite using Moroccan oil, shea moisture shampoo, and coconut oil. She seeks recommendations for a clinic or doctor as previous doctors attributed the issue to stress but offered no solutions.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A user inquired about Hair XL offered by a clinic in the Netherlands, questioning if it is a form of Exosome treatment. The conversation seeks experiences and clarity on the treatment.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A 25-year-old male with normal hormone levels is considering starting finasteride and minoxidil for hair loss but is concerned about high estradiol levels and potential side effects. Responses vary, with some suggesting blood tests before starting treatment and others emphasizing individual tolerance and the importance of consulting a doctor.

The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

A user experienced rapid hair loss and was prescribed Desonide cream for mild Alopecia. They are seeking feedback on its effectiveness and potential side effects.

User tried dutasteride, topical finasteride, oral minox, dermawounding, saw palmetto, pumpkin seed oil, and ketacozonole for hair loss. Improvement was temporary, now trying RU58841 and seeking help.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.

A person with androgenetic alopecia has seen hair improvement using oral minoxidil and finasteride but is concerned about increased body hair. They want to know if stopping minoxidil while continuing hormone replacement therapy and finasteride will cause hair loss.

The user experienced sensitivity and side effects from finasteride and Saw Palmetto, leading to swollen and sensitive breasts, and decided to stop finasteride after two weeks. They are now trying Saw Palmetto, Biotin, and Ashwagandha, while others in the conversation discuss their own experiences with hair loss treatments like minoxidil and finasteride.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

The user is experiencing hair thinning and bald spots, using Nizoral, rosemary oil, fluocinolone, and receiving PRP treatments. They are considering oral minoxidil and finasteride but are hesitant due to age and financial constraints.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

A 19-year-old diagnosed with AGA was refused finasteride by a dermatologist who cited fertility concerns and prescribed minoxidil, vitamins, and shampoos instead. The user is unsure about using minoxidil and considers finding another dermatologist.

Hair loss treatments discussed: Minoxidil, Finasteride, RU58841, and Spironolactone. Woman with androgenetic alopecia and alopecia areata shares experience using Spironolactone.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Creatine may cause increased hair shedding due to androgen receptor sensitivity, despite limited evidence. The user is using dutasteride and minoxidil and seeks advice on whether shedding will stabilize, with suggestions including GHK-Cu and RU58841.